telitacicept
remegen
['telitacicept']
#acr2022 l07: telitacicept - anti-blys and april in sle
335 pts p3 52 wk study tel 160 mg sq q7d vs pbo
83% sri4 response in tel vs 38% pbo (p&lt;0.001)
as early as w4, sustained to w52
most common aes: uris, decr igg/igm, injxn site rxn, uti #acrbest 
Rheumatologist at Institute for Rheumatic and Autoimmune Disease at Overlook Hospital, proud Hopkins alum, health care advocate, Eagles fan entering Giants land